AptarGroup : 2026 Annual Meeting of Stockholders

Published: 2026-05-06 10:24:10 ET ATR

Published on 05/06/2026 at 10:24 am EDT

May 6, 2026

Stephan Tanda, President & CEO

Irene Hudson, EVP, Chief Legal Officer and Secretary

Call to Order and Introductions - Stephan B. Tanda, President and Chief Executive Officer and

Gael Touya, President of Aptar Pharma and CEO Designate

Procedural Formalities - Irene Hudson, Secretary

Affidavit of mailing of Notice of Annual Meeting

Record date and stockholder list

Identification of inspector of election

Statement that quorum is present

Opening of Polls - Irene Hudson, Secretary

Matters to be Voted Upon - Irene Hudson, Secretary

Election of four (4) members to the Board of Directors

Proposal to approve, on an advisory basis, Aptar's executive compensation

Proposal to ratify the appointment of the independent registered public accounting firm for 2026

Closing of Polls - Irene Hudson, Secretary

Announcement of Preliminary Voting Results - Irene Hudson, Secretary

Adjournment - Stephan B. Tanda, President and Chief Executive Officer

Question and Answer Session - Stephan B. Tanda, President and Chief Executive Officer

Stephan B. Tanda

President and Chief Executive Officer

Gael Touya

President, Aptar Pharma President and CEO Designate

Irene Hudson

Executive Vice President, Chief Legal Officer and Secretary

Business Overview

Stephan B. Tanda

President and Chief Executive Officer

Forward Looking Statements & Non-GAAP Financial Measures

This presentation includes forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on management's beliefs and assumptions in light of information currently available to management. Accordingly, the Company's actual results may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in the Company's operations and business environment, including, among other factors, those described in documents filed by the Company with the Securities and Exchange Commission, specifically its Form 10-Ks and 10-Qs. The Company does not assume any obligation to update, amend or clarify such statements to reflect new events, information or circumstances after the date of this presentation.

During the course of this presentation, certain non-GAAP financial information will be presented. Refer to the Appendix at the end of this presentation for additional information and a reconciliation to the most directly comparable GAAP measures. However, we are not able to reconcile forward-looking non-GAAP financial measures because certain reconciling items are dependent on future events that either cannot be controlled, such as exchange rates and changes in the fair value of equity investments, or reliably predicted without unreasonable effort because they are not part of the company's routine activities, such as restructuring and acquisition costs. The variability of these items could have a significant impact on our future GAAP financial results.

We present earnings before net interest and taxes ("EBIT"), earnings before net interest, taxes, depreciation and amortization ("EBITDA") and adjusted earnings per share. We also present our adjusted earnings before net interest and taxes ("Adjusted EBIT"), adjusted earnings before net interest, taxes, depreciation and amortization ("Adjusted EBITDA") and adjusted earnings per share, all of which exclude restructuring initiatives, acquisition-related costs, purchase accounting adjustments related to acquisitions and investments, net unrealized investment gains and losses related to observable market price changes on equity securities and other special items. Adjusted EBITDA margin is adjusted EBITDA divided by reported net sales. For the year ended December 31, 2025 and quarter ended March 31, 2026, "other special items" include costs incurred related to non-ordinary-course litigation, specifically: lawsuits between Aptar and ARS Pharmaceuticals, Inc. involving Aptar's claims of trade-secret misappropriation and contractual breaches and ARS's lawsuit against Aptar under U.S. antitrust laws; and patent infringement actions filed by Nemera La Verpillière SAS in Germany and France relating to certain of Aptar's ophthalmic products. These costs are excluded because they do not reflect our core operating performance. Please refer to "Legal Proceedings" within Note 12 - Commitments and Contingencies within Aptar's Form 10-Q for the quarterly period ended March 31, 2026 for additional information. Our Operations Outlook is also provided on a non-U.S. GAAP basis because certain reconciling items are dependent on future events that either cannot be controlled, such as exchange rates and changes in the fair value of equity investments, or reliably predicted because they are not part of our routine activities, such as restructuring initiatives and acquisition-related costs. Core sales exclude acquisitions and changes in foreign currency sales. Core sales growth is calculated as current sales, less acquisitions, less constant currency prior year sales, divided by constant currency prior year sales. Free cash flow is calculated as cash provided by operating activities less capital expenditures plus proceeds from government grants related to capital expenditures. Return on Investment Capital (ROIC) is calculated as Adjusted Earnings before Net Interest and Taxes, less Tax Effect / Average Capital, whereas Average Capital is the average of beginning of year capital and Capital is Equity plus Debt less Cash. We use free cash flow to measure cash flow generated by operations that is available for dividends, share repurchases, acquisitions and debt repayment.

Millions of People Around the World Use our Products Every Day

Aptar Full Year 2025 Results

2025 % of Total Reported Sales

Beverage 5%

Food

69%

Pharma % of Total FY 2025 Adj EBITDA1

FY 2025

Reported sales increased 5% to $3.8 billion, compared to

$3.6 billion in the prior year

Home Care 3%

Personal Care 16%

10%

Closures 19%

$3.8B2

Beauty 35%

Pharma 46%

Proprietary Drug Delivery Systems3

18%

Beauty % of Total FY 2025 Adj EBITDA1

33%

Core sales were up 2%, reflecting steady demand across key product categories

Reported net income increased 5% to $393 million, and reported earnings per share grew 7% to $5.89, up from $5.53 a year ago.

13%

Closures % of Total FY 2025 Adj EBITDA1

Returned $486 million to shareholders through share repurchases and dividends.

Fragrance, Facial Skincare and Color Cosmetics

20%

Injectables 8%

Active Material Science Solutions 5%

2025 marked our 32nd consecutive year of paying an annually increasing dividend

1: See "Forward-Looking Statements and Non-GAAP Financial Measures" slide for definitions and Appendix for GAAP reconciliation 2: 2025 Annual Revenue

FY 2025 Segment Results*

Aptar Pharma FY 2025 Sales

Aptar Beauty FY 2025 Sales

Aptar Closures FY 2025 Sales

(in millions $)

* Core sales is a non-GAAP financial measure. See "Forward-Looking Statements and Non-GAAP Financial Measures" slide for definitions and Appendix for GAAP reconciliation. 8

Prioritizing Capital Deployment for Highest Returns

We remain focused on selective and disciplined capital allocation

Repurchases - $0.9B

Dividends - $0.9B

17%

66%

CapEx & Acquisitions - $3.5B

Pharma ~50%

Profitable organic growth powered by disciplined capital allocation

Continued emphasis on strategic acquisitions and high-value partnerships

Consistent return of shareholder value through dividends and share repurchases

From 2017-2025:

~Two-thirds of capital reinvested into core business operations and growth initiatives

$1.2 B

Returned to shareholders through dividends and share repurchases

over the last five years

~One-third of capital returned to shareholders

2017 - 2025

First Quarter 2026 Reported Results

$1,200

$1,000

$800

$600

$400

$200

Q1 Reported Sales

(in millions $)

$887

11%

$983

Q1 2025 Q1 2026

$1.40

$1.20

$1.00

$0.80

$0.60

$0.40

$0.20

Q1 Reported EPS

$1.17

-4%

$1.12

Q1 2025 Q1 2026

Flat

Core Sales Growth*

+8%

Currency

Effects

+3%

Acquisitions

25.8%

Q1 2025

Reported Effective Tax Rate

22.4%

Q1 2026

Reported Effective Tax Rate

Recent Recognitions

Our award-winning commitment to sustainability is a competitive advantage that drives impact for our customers

CDP

Climate A List

Newsweek

In the Top 100

America's Most Responsible

Forbes

One of the

World's Top Companies For

TIME

One of the

World's Most Sustainable

EcoVadis

Sustainability Rating

Platinum

Top 1%

Barron's*

In the Top 100

Most Sustainable Companies

ISS ESG

Achieved

Prime Status

USA Today

One of

America's Climate Leaders

2024-2025

Companies

Women

Companies

2021 - 2025

from 2019-2025

from 2020-2024

2023-2026

2020-2026

from 2021-2025

2024-2025

Employee Safety and Engagement

Turning to safety and employee engagement, our goal of zero injuries continues to be the top priority

We further strengthened our leadership development portfolio through continued expansion of our award-winning Corporate University

Our commitment to our communities is reflected in our charitable giving, volunteerism and ongoing participation in local initiatives

Through CARE®, our global employee-supported organization, we amplify our impact by matching employee donations and engaging in fundraising efforts that strengthen our local communities

Board of Directors

Deep experience and knowledge across each of our focused end markets, main regions and key functional areas of expertise, including:

‒ Pharma, CPG, Packaging

‒ Global P&L and Group Leadership, Clevel Finance, Marketing, Operations, Strategy

‒ Portfolio management and restructuring

‒ Public, Private, and PE ownership

Four current or former public company CEOs

Independent Chair, since 1995

George Fotiades

Giovanna Kampouri Monnas

Candace Matthews

Isabel Marey-Semper

Ralf Wunderlich

Stephan Tanda

Craig Owens

Matt Trerotola

Sarah Glickman

Julie Xing

Value Creation Framework

Reinvest in profitable growth

Strong Balance Sheet that Provides Optionality

Focused on Cost Management & Operational Leverage

Enhancing Value Through Strategic Capital Allocation

Technology,

Innovation & Sustainability Leader

Active in

Growing End Markets, with a Leading Position in Key Categories

4-7%

Core Sales Growth1

21-23%

Adjusted EBITDA Margin1

11-13%

ROIC1

30-40%

Dividend Payout Ratio1

Long Term Targets

1: See "Forward-Looking Statements and Non-GAAP Financial Measures" slide for definition. 14

Q&A

Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited)

(: In Thousands)

Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited)

(: In Thousands)

Reconciliation of Adjusted Earnings Per Diluted Share (Unaudited)

(: In Thousands Except Per Share Data)

Reconciliation of Adjusted Earnings Per Diluted Share (Unaudited)

(: In Thousands Except Per Share Data)

Disclaimer

AptarGroup Inc. published this content on May 06, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 06, 2026 at 14:23 UTC.